CoreAge Rx vs Velvet Rx
Two GLP-1 providers, one scoreboard. We put CoreAge Rx and Velvet Rx head-to-head on the published Brief Score — the same six factors, scored the same way.
CoreAge Rx
The verdict
CoreAge Rx takes this head-to-head.
CoreAge Rx scores 94 to 63 on our six-factor Brief Score — CoreAge publishes different starting offers across its pages; the advertised annual rates require a full year paid upfront.
That doesn't make Velvet Rx a bad call — it's best for readers who obtain the exact prescription, payment period and written cancellation agreement before choosing a low starting amount. Weigh the six factors below against your own priorities before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both providers scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| Compare | CoreAge Rx | Velvet Rx |
|---|---|---|
| Brief Score | 94/100 (A) | 63/100 (C) |
| Semaglutide | From $79/mo Annual offer: 12 months paid upfront, from $948. Main site: from $99/mo; confirm the selected offer. Full price detailsFrom $79/mo on the annual-plan landing offer, based on a 12-month plan paid in full ($948 at that starting rate); main product page separately advertises from $99/mo | $99 promotional four-week injection supply Doctor consultation, medical support, prescription and shipping advertised included. Exact preparation/dose and next renewal charge unconfirmed. Displayed $299 comparison is not a proven renewal price. Oral offer $149 covers four packs, with duration unconfirmed; processed orders and appointments have separate refund conditions. Full price detailsSemaglutide injection and tablet options advertised; exact preparation and complete selected-plan quote unknown; injection $99 today for four weeks of medicine with care and shipping; displayed $299 comparison is not a confirmed renewal price |
| Tirzepatide | From $129/mo Annual offer: 12 months paid upfront, from $1,548. Main site: from $149/mo; confirm the selected offer. Full price detailsFrom $129/mo on the annual-plan landing offer, based on a 12-month plan paid in full ($1,548 at that starting rate); main product page separately advertises from $149/mo | $179 promotional four-week injection supply Doctor consultation, medical support, prescription and shipping advertised included. Exact preparation/dose and next renewal charge unconfirmed. Displayed $359 comparison is not a proven renewal price. Oral offer $149 covers four packs, with duration unconfirmed; processed orders and appointments have separate refund conditions. Full price detailsTirzepatide injection and tablet options advertised; exact preparation and complete selected-plan quote unknown; injection $179 today for four weeks of medicine with care and shipping; displayed $359 comparison is not a confirmed renewal price |
| Coverage | US only; restrictions by state, confirmed at intake | Available in certain U.S. states under the terms; current treatment-specific state coverage requires confirmation |
| Brand-name access | Not confirmed | A generic FDA-approved-medication banner does not identify a named branded prescribing program or establish the preparation of each advertised injection/tablet. |
| Oral / sublingual | Injection only | Yes |
| On the tracker | Stableprice stable | Newnew to the tracker, no prior reading |
CoreAge Rx: The checked annual-plan offer starts at $79/$129 per month on annual prepay; the main product pages still show $99/$149. Confirm the selected offer.
Velvet Rx: Injection promotions $99/$179 cover four weeks of medicine plus care/shipping. Displayed $299/$359 comparison amounts are not confirmed renewal charges. Oral $149 covers four packs, with duration unconfirmed.
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.